key: cord-0920261-8gatg886
authors: Khan, Irfan A.; Zaid, Musa B.; Gold, Peter A.; Austin, Matthew S.; Parvizi, Javad; Bedard, Nicholas A.; Jevsevar, David S.; Hannon, Charles P.; Fillingham, Yale A.
title: Making a Joint Decision Regarding The Timing of Surgery For Elective Arthroplasty Surgery After Being Infected With COVID-19: A Systematic Review
date: 2022-05-06
journal: J Arthroplasty
DOI: 10.1016/j.arth.2022.05.006
sha: 554ca467213dad1073221c2d2206e10b44a00107
doc_id: 920261
cord_uid: 8gatg886

INTRODUCTION: The Coronavirus Disease 2019 (COVID-19) pandemic has caused a significant number of patients to have their elective arthroplasty surgeries rescheduled. While it is established that patients with COVID-19 who are undergoing surgery have a significantly higher risk of experiencing postoperative complications and mortality, it is not well-known at what time after testing positive the risk of postoperative complications or mortality returns to normal. METHODS: PubMed (MEDLINE), EMBASE, and professional society websites were systematically reviewed on March 7(th), 2022 to identify studies and guidelines on the optimal timeframe to reschedule patients for elective surgery after preoperatively testing positive for COVID-19. Outcomes included postoperative complications such as mortality, pneumonia, acute respiratory distress syndrome, septic shock, and pulmonary embolism. RESULTS: A total of 14 studies and professional society guidelines met the inclusion criteria for this systematic review. Patients with asymptomatic COVID-19 should be rescheduled 4-8 weeks after testing positive (as long as they do not develop symptoms in the interim), patients with mild/moderate COVID-19 should be rescheduled 6-8 weeks after testing positive (with complete resolution of symptoms), and patients with severe/critical COVID-19 should be rescheduled at a minimum of 12 weeks after hospital discharge (with complete resolution of symptoms). DISCUSSION/CONCLUSIONS: Given the negative association between preoperative COVID-19 and postoperative complications, patients should have elective arthroplasty surgery rescheduled at differing timeframes based on their symptoms. Additionally, a multidisciplinary and patient-centered approach to rescheduling patients is recommended. Further study is needed to examine the impact of novel COVID-19 variants and vaccination on timeframes for rescheduling surgery.

The Coronavirus Disease 2019 (COVID-19) pandemic has caused unimaginable levels of 28 disruption for patients undergoing orthopaedic procedures and healthcare professionals providing 29 care worldwide. 1,2 Surgeons and patients are faced with rapidly changing regulations at local and 30 national levels as COVID-19 case volumes peak and trough with novel variants of concern. 31 Patients suffering from debilitating conditions such as hip and knee osteoarthritis have had 32 elective procedures such as total hip and knee arthroplasty cancelled due to numerous reasons, 33 including national lockdowns, inadequate medical staffing, personal protective equipment (PPE) 34

shortages, and positive COVID-19 tests during pre-admission testing. 3,4 35 A less common reason for surgical cancellations was patients having positive COVID-19 36 tests during pre-admission testing, with pre-admission testing positivity rates ranging from 37 0.21% to 0.79%. 5,6 However, during the past few months, there was a spike of COVID-19 cases primarily focused on reducing infection transmission and not focused on the risks of the patient 50 undergoing the procedure. Therefore, we conducted this systematic review to determine the 51 optimal timeframe to reschedule patients for elective arthroplasty surgery after being diagnosed 52 with COVID-19 preoperatively, focusing on timeframes that decrease their risk of experiencing 53 postoperative complications such as pneumonia, respiratory failure, and mortality back to the 54 baseline risk. We hypothesized that patients who test positive for COVID-19 preoperatively 55 should be rescheduled for elective arthroplasty surgery 1 -3 months after their positive COVID-56 19 test, depending on the presence of symptoms and symptom severity. 57 J o u r n a l P r e -p r o o f Timing of Surgery after Methods 58

In an effort to provide orthopaedic surgeons and healthcare systems with evidence-based 59 recommendations regarding preoperative COVID-19 testing and timeframes to reschedule 60 discussed the query and came to a consensus. After title and abstract screening, full-text review 81 was conducted by three authors (IAK, MBZ, PAG), who convened with the principal 82 investigator (YAF) to discuss discrepancies and arrive at a consensus about final study inclusion. 83

This systematic review included randomized controlled trials (RCT), prospective non-84 randomized studies, and retrospective cohort studies. To be considered for inclusion, all studies 85 must have examined the impact of being diagnosed with COVID-19 preoperative in humans 86 undergoing elective surgery, report the amount of time that patients were diagnosed with 87 COVID-19 prior to undergoing surgery, and include a comparison group of patients who were 88 not diagnosed with COVID-19 preoperatively. Studies were excluded if they were case reports 89 and case series, if they examined the impact of COVID-19 in non-human species, and if they had 90 no comparison group of COVID-19 negative patients. 91

The primary outcomes for this study were the risk/odds of experiencing postoperative 93 pneumonia, postoperative respiratory failure, and postoperatively mortality. Secondary outcomes 94 include postoperative deep vein thrombosis (DVT), pulmonary embolism (PE), arrhythmia, 95 urinary tract infection, sepsis, or any postoperative complication. For each outcome, the odds 96 ratios will be examined for experiencing those complications between different timeframes of 97 when patients were diagnosed with COVID-19 prior to surgery, and compared to patients who 98 were COVID-19 negative. 99

Given the limited number of studies expected to be published on this topic, a qualitative 100 synthesis of the data was planned, with no meta-analysis. Three authors (IAK, MBZ, PAG) 101 conducted the qualitative data extraction and synthesis, which was reviewed by the principal The qualitative synthesis was conducted by examining what timeframes patients  105   underwent surgery after being diagnosed with COVID-19 (0-2 weeks, 2-3 weeks, 3-4 weeks, 4-5  106 weeks, 5-6 weeks, 6-7 weeks, 7-8 weeks, > 8 weeks). After doing that, complication rates were 107 examined in each timeframe, and it was determined whether patients were at an increased risk of 108 sustaining complications during a specific timeframe when compared to COVID-19 negative 109 patients undergoing surgery. Statistical significance was defined as the odds ratio (OR) for 110 sustaining a complication being > 1, with the entire 95% confidence interval (CI) being > 1. 

The articles in this systematic review were reviewed independently by three authors 119 (IAK, ZBM, PAG) using the Newcastle-Ottawa risk-of-bias tool to evaluate for risk of bias. 19 120

The three authors convened to reach consensus on the designations for risk-of-bias assessments. (Table I) . 165

Butyrskii et al. conducted a multi-center prospective cohort study in Russia to determine 166 the optimal timeframe for patients to undergo elective surgery after testing positive for COVID-167

were COVID negative. The main outcome for this study was 30-day postoperative mortality. The 169 authors found that patients had an increased odds of mortality when having surgery 0-8 weeks 170 after being diagnosed with COVID-19, which decreased for patients who underwent surgery 171 more than 8 weeks after a positive COVID-19 test (Table I, Figure II ). However, patients who 172 underwent surgery more than 8 weeks after a positive COVID-19 test and still had active 173 symptoms had an increased odds of mortality. While these results support the previous studies, 174 two significant limitations include the study had a low number of COVID-19 positive patients, 175

and we were only able to access the abstract due to the full-text being written in Russian. 

The AA/RCS consensus statements suggested waiting 7 weeks after testing positive for 194 COVID-19 to schedule elective surgery (Table II) . 31,32 The ESSKA guidelines suggest waiting a 195 minimum of 8 weeks after testing positive for COVID-19 to reschedule elective surgery (Table  196 II). 34 These recommendations differ from the ASA/APSF guidelines, which recommended 197 rescheduling elective surgery after 4 weeks for asymptomatic patients, 6 weeks for with 198 mild/moderate symptoms, and 12 weeks for severe/critical COVID-19 (Table II) . 30 The 199 ASA/APSF guidelines used a limited number of studies with small sample sizes to support their 200 recommendation. 30 The EHS and EKA guidelines mentioned no specific timeframe for 201 postponement in patients with a positive COVID-19 RT-PCR test, while suggesting waiting 3 202 weeks was a reasonable time, with no supporting evidence (Table II) Prevention (CDC) time-based approach or symptom-based approach for rescheduling 205 patients, 28,29 without recommending specific rescheduling timeframes (Table II) . 206

Based on information synthesized from the aforementioned studies and professional 208 organization guidelines, the following timeframes should be considered for rescheduling patients 209 who are undergoing elective arthroplasty surgery after testing positive for COVID-19 210 preoperatively ( Figure V) , based on their COVID-19 severity (Table III) 

The ideal timeframe for rescheduling elective arthroplasty surgery, with the goal of 317 minimizing the risk of morbidity and mortality following surgery after a positive COVID-19 test, 318

is not well defined. Based upon the best available evidence and professional organization 319 recommendations, we sought to provide timeframe recommendations for rescheduling patients 320 who are undergoing elective arthroplasty surgery following a positive COVID-19 test. Surgeons 321 and patients will likely be confronted with differing guidelines from local, state, and federal 322 governments as well as policies from their local hospital or health system. We hope that through 323 an awareness of the current best available evidence and understanding of its limitations, surgeons 324 are equipped to help patients determine the optimal time to reschedule surgery that helps to 325 account for each patient's individual circumstance. 326 J o u r n a l P r e -p r o o f Tables 530 Table I J o u r n a l P r e -p r o o f 

COVID-19: persistence of symptoms and lung 474 alterations after 3-6 months from hospital discharge

Six-Month Outcomes in Patients Hospitalized with 477

Severe COVID-19

Long-COVID': a cross-sectional study of persisting 480 symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Associated With Persistent COVID-19 PCR Positivity

Mortality and pulmonary complications in 486 patients undergoing surgery with perioperative SARS-CoV-2 infection: an international 487 cohort study. The Lancet

Risk stratification of individuals undergoing surgery 489 after COVID-19 recovery

Shared Decision-making in Orthopaedic Surgery

Informed, Patient-Centered Decisions Associated 494 with Better Health Outcomes in Orthopedics: Prospective Cohort Study. Med Decis 495 Making

Early assessment of the clinical severity of the SARS-497

CoV-2 omicron variant in South Africa: a data linkage study. The Lancet

Clinical severity of, and effectiveness of 500 mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in 501 the United States: prospective observational study

The SARS-CoV-2 B.1.1.529 Omicron Virus 504 Causes Attenuated Infection and Disease in Mice and Hamsters

The Omicron (B.1.1.529) SARS-CoV-2 Variant of 507 Concern Does Not Readily Infect Syrian Hamsters. Microbiology

Abbreviations DVT = deep vein thrombosis

ARDS = acute respiratory distress syndrome. Pulmonary Complications (COVIDSurg Study) = Pneumonia, ARDS, and Unexpected Mechanical Ventilation Timeframes (Vary for Each Study)

Baiocchi 2020 Cohort **** ** * 7Butyrskii 2021 Cohort ----COVIDSurg 2021 Cohort **** ** *** 9Deng 2021 Cohort **** ** *** 9Kothari 2021 Cohort **** ** *** 9Lal 2021 Cohort **** ** *** 9Larsen 2021 Cohort *** ** 5Pandrowala 2021 Cohort **** ** 6 *Abbreviations: -= Not applicable due to not having the full-text in English.

J o u r n a l P r e -p r o o f Deng 2021 Cohort **** ** *** 9Kothari 2021 Cohort **** ** *** 9Lal 2021 Cohort **** ** *** 9Larsen 2021 Cohort *** ** 5Pandrowala 2021 Cohort **** ** 6 *Abbreviations: -= Not applicable due to not having the full-text in English.